• Je něco špatně v tomto záznamu ?

Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54

RHM. Furtado, JC. Nicolau, G. Magnani, K. Im, DL. Bhatt, RF. Storey, PG. Steg, J. Spinar, A. Budaj, F. Kontny, R. Corbalan, RG. Kiss, MT. Abola, P. Johanson, EC. Jensen, E. Braunwald, MS. Sabatine, MP. Bonaca

. 2020 ; 41 (17) : 1625-1632. [pub] 20200501

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020570

AIMS: PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients with prior myocardial infarction (MI). While much of the discussion around prolonged DAPT has been focused on stented patients, patients with prior MI without prior coronary stenting comprise a clinically important subgroup. METHODS AND RESULTS: This was a pre-specified analysis from PEGASUS-TIMI 54, which randomized 21 162 patients with prior MI (1-3 years) and additional high-risk features to ticagrelor 60 mg, 90 mg, or placebo twice daily in addition to aspirin. A total of 4199 patients had no history of coronary stenting at baseline. The primary efficacy outcome (MACE) was the composite of cardiovascular death, MI, or stroke. Patients without history of coronary stenting had higher baseline risk of MACE [13.2% vs. 8.0%, adjusted hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.15-1.73, in the placebo arm]. The relative risk reduction in MACE with ticagrelor (pooled doses) was similar in patients without (HR 0.82, 95% CI 0.68-0.99) and with prior stenting (HR 0.85, 95% CI 0.75-0.96; P for interaction = 0.76). CONCLUSION: Long-term ticagrelor reduces thrombotic events in patients with prior MI regardless of whether they had prior coronary stenting. These data highlight the benefits of DAPT in prevention of spontaneous atherothrombotic events and indicate that long-term ticagrelor may be considered in high-risk patients with prior MI even if they have not been treated with stenting. CLINICALTRIALS.GOV IDENTIFIER: NCT01225562.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020570
003      
CZ-PrNML
005      
20210830102220.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehz821 $2 doi
035    __
$a (PubMed)31811715
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Furtado, Remo H M $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA $u Instituto do Coracao (InCor), Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo, Av Dr Eneas de Carvalho Aguiar 44, 05403 Sao Paulo, Brazil
245    10
$a Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54 / $c RHM. Furtado, JC. Nicolau, G. Magnani, K. Im, DL. Bhatt, RF. Storey, PG. Steg, J. Spinar, A. Budaj, F. Kontny, R. Corbalan, RG. Kiss, MT. Abola, P. Johanson, EC. Jensen, E. Braunwald, MS. Sabatine, MP. Bonaca
520    9_
$a AIMS: PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients with prior myocardial infarction (MI). While much of the discussion around prolonged DAPT has been focused on stented patients, patients with prior MI without prior coronary stenting comprise a clinically important subgroup. METHODS AND RESULTS: This was a pre-specified analysis from PEGASUS-TIMI 54, which randomized 21 162 patients with prior MI (1-3 years) and additional high-risk features to ticagrelor 60 mg, 90 mg, or placebo twice daily in addition to aspirin. A total of 4199 patients had no history of coronary stenting at baseline. The primary efficacy outcome (MACE) was the composite of cardiovascular death, MI, or stroke. Patients without history of coronary stenting had higher baseline risk of MACE [13.2% vs. 8.0%, adjusted hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.15-1.73, in the placebo arm]. The relative risk reduction in MACE with ticagrelor (pooled doses) was similar in patients without (HR 0.82, 95% CI 0.68-0.99) and with prior stenting (HR 0.85, 95% CI 0.75-0.96; P for interaction = 0.76). CONCLUSION: Long-term ticagrelor reduces thrombotic events in patients with prior MI regardless of whether they had prior coronary stenting. These data highlight the benefits of DAPT in prevention of spontaneous atherothrombotic events and indicate that long-term ticagrelor may be considered in high-risk patients with prior MI even if they have not been treated with stenting. CLINICALTRIALS.GOV IDENTIFIER: NCT01225562.
650    _2
$a adenosin $x terapeutické užití $7 D000241
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a lidé $7 D006801
650    12
$a infarkt myokardu $x farmakoterapie $x prevence a kontrola $7 D009203
650    _2
$a inhibitory agregace trombocytů $x škodlivé účinky $7 D010975
650    12
$a antagonisté purinergních receptorů P2Y $x terapeutické užití $7 D058921
650    _2
$a sekundární prevence $7 D055502
650    _2
$a ticagrelor $x terapeutické užití $7 D000077486
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nicolau, Jose C $u Instituto do Coracao (InCor), Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo, Av Dr Eneas de Carvalho Aguiar 44, 05403 Sao Paulo, Brazil
700    1_
$a Magnani, Giulia $u University Hospital of Parma, Via Gramsci, 14, 43126 Parma PR, Italy
700    1_
$a Im, Kyungah $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
700    1_
$a Bhatt, Deepak L $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
700    1_
$a Storey, Robert F $u University of Sheffield, Western Bank, Sheffield S10 2TN, UK
700    1_
$a Steg, P Gabriel $u Assistance Publique-Hôpitaux de Paris, 3 Avenue Victoria, 75004 Paris, France
700    1_
$a Spinar, Jindrich $u University Hospital Brno, 20 Jihlavska, Brno, Czech Republic
700    1_
$a Budaj, Andrzej $u Centre of Postgraduate Medical Education, Grochowski Hospital, Grenadierów 51/59, 04-073 Warsaw, Poland
700    1_
$a Kontny, Frederic $u Department of Cardiology, Stavanger University Hospital, Gerd Ragna Bloch Thorsens gate 8, Stavanger, Norway $u Drammen Heart Center, Dronninggata 28, 3004 Drammen, Norway
700    1_
$a Corbalan, Ramon $u Cardiovascular Division, Faculty of Medicine, Pontificia Universidad Católica de Chile, Lira 40, Santiago, Chile
700    1_
$a Kiss, Robert G $u Department of Cardiology, Military Hospital, Róbert Károly krt., 1134 Budapest, Hungary
700    1_
$a Abola, Maria Teresa $u College of Medicine, University of the Philippines/Philippine Heart Center, East, Quezon City, Metro Manila, Philippines
700    1_
$a Johanson, Per $u AstraZeneca, 431 53 Mölndal, Sweden
700    1_
$a Jensen, Eva C $u AstraZeneca, 431 53 Mölndal, Sweden
700    1_
$a Braunwald, Eugene $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
700    1_
$a Sabatine, Marc S $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
700    1_
$a Bonaca, Marc P $u TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA $u CPC Clinical Research, University of Colorado School of Medicine, 13199 E Montview Blvd Suite 200, Aurora, CO, USA
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 41, č. 17 (2020), s. 1625-1632
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31811715 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102220 $b ABA008
999    __
$a ok $b bmc $g 1691194 $s 1141016
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 41 $c 17 $d 1625-1632 $e 20200501 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace